Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria
Chin-Chung Wu1, Mei-Ling Chan, Wen-Ying Chen
1Graduate Institute of Natural Products, Kaohsiung Medical University, 100 Shin-Chuan 1st Road, Kaohsiung, Taiwan. ccwu@kmu.edu.tw
Abstract:
Pristimerin, a naturally occurring triterpenoid, has been shown to cause cytotoxicity in several cancer cell lines. However, the mechanism for the cytotoxic effect of pristimerin was never explored. In the present study, human breast cancer MDA-MB-231 cells treated with pristimerin (1 and 3 micromol/L) showed rapid induction of apoptosis, as indicated by caspase activation, DNA fragmentation, and morphologic changes. Pretreatment of a pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) completely prevented pristimerin-induced apoptosis. Treatment of tumor cells with pristimerin resulted in a rapid release of cytochrome c from mitochondria, which preceded caspase activation and the decrease of mitochondrial membrane potential. In addition, neither benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone nor permeability transition pore inhibitor cyclosporin A markedly prevented pristimerin-induced mitochondrial cytochrome c release. Pristimerin did not significantly alter the protein level of Bcl-2 family members (Bcl-2, Bcl-X(L), and Bax), nor did it induce Bax translocation. Moreover, Bcl-2 overexpression fails to prevent pristimerin-induced apoptosis. The generation of reactive oxygen species in MDA-MB-231 cells was also not affected by pristimerin. In a cell-free system, pristimerin induced cytochrome c release from isolated mitochondria. Taken together, these results suggested that pristimerin is a novel mitochondria-targeted compound and may be further evaluated as a chemotherapeutic agent for human cancer.
Insights
Pristimerin induces apoptosis in human breast cancer cells by directly targeting mitochondria, leading to cytochrome c release. This natural compound shows potential as a novel chemotherapeutic agent for cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Pristimerin, a natural triterpenoid, exhibits cytotoxicity against various cancer cell lines.
- The precise mechanism underlying pristimerin's cytotoxic effects remains largely unexplored.
Purpose of the Study:
- To elucidate the mechanism of pristimerin-induced cytotoxicity in human breast cancer cells.
- To investigate pristimerin's effects on apoptosis and mitochondrial function.
Main Methods:
- Human breast cancer MDA-MB-231 cells were treated with pristimerin.
- Assays included caspase activation, DNA fragmentation, mitochondrial membrane potential, and cytochrome c release.
- Involvement of Bcl-2 family proteins and reactive oxygen species was assessed.
- Cell-free experiments with isolated mitochondria were performed.
Main Results:
- Pristimerin rapidly induced apoptosis, evidenced by caspase activation and DNA fragmentation.
- Mitochondrial cytochrome c release preceded caspase activation and was independent of Bcl-2 family proteins or reactive oxygen species.
- Pristimerin directly induced cytochrome c release from isolated mitochondria.
- Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (a pan-caspase inhibitor) blocked apoptosis, but not cytochrome c release.
Conclusions:
- Pristimerin is a novel mitochondria-targeted compound.
- Its mechanism involves direct induction of mitochondrial cytochrome c release, triggering apoptosis.
- Pristimerin warrants further investigation as a potential chemotherapeutic agent for human cancers.
Related Concept Videos
Abnormal Proliferation
Apoptosis
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy


